|
JO3474B1
(ar)
|
2014-08-29 |
2020-07-05 |
Amgen Inc |
مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
|
|
WO2017147410A1
(en)
*
|
2016-02-25 |
2017-08-31 |
Amgen Inc. |
Compounds that inhibit mcl-1 protein
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
EP3454862B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
EP3455219A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
WO2017197055A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
WO2018015526A1
(en)
|
2016-07-22 |
2018-01-25 |
Les Laboratoires Servier |
Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
|
|
JP6453507B2
(ja)
|
2017-03-30 |
2019-01-16 |
アムジエン・インコーポレーテツド |
Ｍｃｌ−１タンパク質を阻害する化合物
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
US20200239494A1
(en)
*
|
2017-08-15 |
2020-07-30 |
Abbvie Inc. |
Macrocyclic mcl-1 inhibitors and methods of use
|
|
SG11202001182QA
(en)
*
|
2017-08-15 |
2020-03-30 |
Abbvie Inc |
Macrocyclic mcl-1 inhibitors and methods of use
|
|
ES3036998T3
(en)
|
2017-08-18 |
2025-09-26 |
Amgen Inc |
Compounds that inhibit mcl-1 protein
|
|
EP3676270A1
(en)
|
2017-08-29 |
2020-07-08 |
Amgen Inc. |
Macrocyclic compounds that inhibit mcl-1 protein
|
|
EP3762393B1
(en)
|
2018-03-05 |
2023-01-11 |
Amgen Inc. |
Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists
|
|
KR20240165483A
(ko)
*
|
2018-05-14 |
2024-11-22 |
길리애드 사이언시즈, 인코포레이티드 |
Mcl-1 억제제
|
|
MA54157A
(fr)
|
2018-11-09 |
2021-09-15 |
Prelude Therapeutics Inc |
Dérivés de spiro-sulfonamide en tant qu'inhibiteurs de la protéine de la leucémie myéloïde -1 (mcl-1)
|
|
CN113453679B
(zh)
|
2018-12-20 |
2025-07-08 |
C4医药公司 |
靶向蛋白降解
|
|
WO2020147802A1
(en)
*
|
2019-01-18 |
2020-07-23 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Macrocyclic spiroethers as mcl-1 inhibitors
|
|
CA3136088A1
(en)
|
2019-05-20 |
2020-11-26 |
Matthew T. Burger |
Mcl-1 inhibitor antibody-drug conjugates and methods of use
|
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
|
JP7617861B2
(ja)
*
|
2019-06-21 |
2025-01-20 |
ヤンセン ファーマシューティカ エヌ．ベー． |
Ｍｃｌ－１の大環状阻害剤
|
|
UA129329C2
(uk)
|
2019-06-25 |
2025-03-19 |
Гіліад Сайєнсіз, Інк. |
ЗЛИТІ БІЛКИ FLT3L-Fc
|
|
MX2022000390A
(es)
|
2019-07-09 |
2022-02-10 |
Janssen Pharmaceutica Nv |
Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
|
|
EP3771469A1
(en)
*
|
2019-07-30 |
2021-02-03 |
Amgen, Inc |
Formulations and dosages for administering a compound that inhibits mcl1 protein
|
|
WO2021047616A1
(zh)
*
|
2019-09-12 |
2021-03-18 |
苏州亚盛药业有限公司 |
氧氮杂环庚烷类螺环化合物、中间体及其制备方法
|
|
CN118178645A
(zh)
|
2019-10-18 |
2024-06-14 |
四十七公司 |
用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
|
|
CA3153636A1
(en)
|
2019-10-31 |
2021-05-06 |
Forty Seven, Inc. |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
TW202132315A
(zh)
*
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras 抑制劑
|
|
AU2020379734B2
(en)
|
2019-11-04 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
PL4065567T3
(pl)
*
|
2019-11-26 |
2025-01-20 |
Gilead Sciences, Inc. |
Procesy i związki pośrednie do wytwarzania inhibitorów mcl1
|
|
AU2020412875A1
(en)
|
2019-12-24 |
2022-06-23 |
Carna Biosciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
PH12022552122A1
(en)
|
2020-02-14 |
2024-01-29 |
Jounce Therapeutics Inc |
Antibodies and fusion proteins that bind to ccr8 and uses thereof
|
|
AU2021222332A1
(en)
*
|
2020-02-21 |
2022-10-20 |
Janssen Pharmaceutica Nv |
Macrocyclic indole derivatives as inhibitors of MCL-1
|
|
JP2021161114A
(ja)
*
|
2020-03-31 |
2021-10-11 |
アムジエン・インコーポレーテツド |
Ｍｃｌ−１化合物のメチル化
|
|
US20230212191A1
(en)
*
|
2020-04-16 |
2023-07-06 |
Prelude Therapeutics, Incorporated |
Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
|
|
AU2021264550A1
(en)
|
2020-05-01 |
2022-11-17 |
Gilead Sciences, Inc. |
CD73 inhibiting 2,4-dioxopyrimidine compounds
|
|
ES3038201T3
(en)
*
|
2020-05-06 |
2025-10-10 |
Amgen Inc |
Synthesis of vinylic protected alcohol intermediates
|
|
CA3180566A1
(en)
*
|
2020-05-06 |
2021-11-11 |
Amgen Inc. |
Synthesis of sulfonamide intermediates
|
|
TWI827924B
(zh)
|
2020-05-06 |
2024-01-01 |
美商安進公司 |
大環Mcl-1抑制劑中間體的閉環合成
|
|
TWI867217B
(zh)
*
|
2020-05-06 |
2024-12-21 |
美商安進公司 |
乙烯基環丁基中間體之合成
|
|
CA3181189A1
(en)
|
2020-05-06 |
2021-11-11 |
Amgen Inc. |
Synthesis of vinylic alcohol intermediates
|
|
WO2021250102A1
(en)
|
2020-06-10 |
2021-12-16 |
Janssen Pharmaceutica Nv |
Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1
|
|
MX2023002691A
(es)
*
|
2020-09-03 |
2023-05-03 |
Amgen Inc |
Desimetrización de diol mediante sustitución aromática nucleófila.
|
|
CN117683049A
(zh)
|
2020-09-15 |
2024-03-12 |
锐新医药公司 |
作为ras抑制剂以治疗癌症的吲哚衍生物
|
|
US12202782B2
(en)
*
|
2020-11-19 |
2025-01-21 |
Gilead Sciences, Inc. |
Processes and intermediates for preparing MCL1 inhibitors
|
|
EP4251208A1
(en)
|
2020-11-24 |
2023-10-04 |
Novartis AG |
Mcl-1 inhibitor antibody-drug conjugates and methods of use
|
|
EP4251604A1
(en)
*
|
2020-11-25 |
2023-10-04 |
Amgen Inc. |
Enantioselective alkenylation of aldehydes
|
|
EP4008324A1
(en)
|
2020-12-07 |
2022-06-08 |
Cellestia Biotech AG |
Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
|
|
US20240041884A1
(en)
|
2020-12-07 |
2024-02-08 |
Cellestia Biotech Ag |
Pharmaceutical Combinations for Treating Cancer
|
|
ES3026771T3
(en)
|
2020-12-17 |
2025-06-12 |
Janssen Pharmaceutica Nv |
Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
CA3215312A1
(en)
|
2021-04-26 |
2022-11-03 |
Frederik Jan Rita Rombouts |
Macrocyclic 2-allyltetrahydrofurans as inhibitors of mcl-1
|
|
EP4334325A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
|
US20220389394A1
(en)
|
2021-05-18 |
2022-12-08 |
Gilead Sciences, Inc. |
METHODS OF USING FLT3L-Fc FUSION PROTEINS
|
|
US11957693B2
(en)
|
2021-06-11 |
2024-04-16 |
Gilead Sciences, Inc. |
Combination MCL-1 inhibitors with anti-cancer agents
|
|
EP4351657A1
(en)
|
2021-06-11 |
2024-04-17 |
Gilead Sciences, Inc. |
Combination mcl-1 inhibitors with anti-body drug conjugates
|
|
KR20240023629A
(ko)
|
2021-06-23 |
2024-02-22 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
KR20240023628A
(ko)
|
2021-06-23 |
2024-02-22 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
CN117396478A
(zh)
|
2021-06-23 |
2024-01-12 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
AU2022375782A1
(en)
|
2021-10-28 |
2024-05-02 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
US11919869B2
(en)
|
2021-10-29 |
2024-03-05 |
Gilead Sciences, Inc. |
CD73 compounds
|
|
WO2023088894A1
(en)
|
2021-11-16 |
2023-05-25 |
Janssen Pharmaceutica Nv |
Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1
|
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
CN118488946A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
CA3237577A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
ES2999273T3
(en)
|
2022-03-17 |
2025-02-25 |
Gilead Sciences Inc |
Ikaros zinc finger family degraders and uses thereof
|
|
JP2025509662A
(ja)
|
2022-03-24 |
2025-04-11 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｔｒｏｐ－２発現がんを治療するための併用療法
|
|
AU2023249146A1
(en)
|
2022-04-05 |
2024-10-10 |
Amgen Inc. |
Salt forms and solvates of mci-1 antagonists
|
|
WO2023196361A1
(en)
*
|
2022-04-05 |
2023-10-12 |
Amgen Inc. |
Amorphous and crystalline forms of mci-1 antagonists
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
KR20250004824A
(ko)
|
2022-04-21 |
2025-01-08 |
길리애드 사이언시즈, 인코포레이티드 |
Kras g12d 조절 화합물
|
|
EP4525927A1
(en)
|
2022-05-20 |
2025-03-26 |
Novartis AG |
Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
|
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
AU2023409398A1
(en)
|
2022-12-22 |
2025-06-05 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024215754A1
(en)
|
2023-04-11 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2024220917A1
(en)
|
2023-04-21 |
2024-10-24 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025006720A1
(en)
|
2023-06-30 |
2025-01-02 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20250100998A1
(en)
|
2023-07-26 |
2025-03-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025024663A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
EP4516807A1
(en)
|
2023-08-28 |
2025-03-05 |
Consorcio Centro de Investigación Biomédica en Red |
Compositions for use in a method of providing improved hematopoietic stem cell engraftment
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025111431A1
(en)
|
2023-11-22 |
2025-05-30 |
Les Laboratoires Servier |
Anti-cd7 antibody-drug conjugates and methods of use thereof
|
|
WO2025111450A1
(en)
|
2023-11-22 |
2025-05-30 |
Les Laboratoires Servier |
Anti-cd74 antibody-drug conjugates and methods of use thereof
|
|
TW202530255A
(zh)
|
2023-12-15 |
2025-08-01 |
法商亞維西亞有限公司 |
抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
US20250376484A1
(en)
|
2024-05-21 |
2025-12-11 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|